Medicines Company News

On January 5, 2023, Boehringer Ingelheim announced that its innovative drug MDM2-p53 antagonist BI 907828 for the first-line treatment of dedifferentiated liposarcoma (DDLPS) Phase II. /III. clinical

Poster display : The highly selective irreversible FGFR inhibitor Gunagratinib in previously treated patients with locally advanced or metastatic FGFR gene abnormalities with cholangiocarcinoma: a phase IIa dose expansion study Summary code: 572 Sub-venue: Poster venue B: Pancreatic cancer, small bowel cancer and hepatobiliary cancer When: January 20, 12:00 PM - 1:30 PM US time : Professor Guo Ye ={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).

On December 28, 2022, InnoCare (SSE: 688428; Hong Kong Stock Exchange code: 09969) today announced that tafasitamab in combination with lenalidomide has been approved by the Hong Kong Department of Health for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplantation.

Yuyue Medical responded that the company's production and operation are legal and compliant, and there is no price increase in oximeter products at present, and discounts and discounts have been canceled due to rising costs.

js?cdnversion='+~(-new Date()/36e5)];The novel coronavirus mRNA epidemic seedling CS-2034 (hereinafter referred to as "CS-2034"), jointly developed by CanSino Biologics Co. js?cdnversion='+~(-new Date()/36e5)];The novel coronavirus mRNA epidemic seedling CS-2034 (hereinafter referred to as "CS-2034"), jointly developed by CanSino Biologics Co.

Kangzhi Pharmaceutical responded to investors on the interactive platform on the 3rd that the company has produced and sold montmorillonite, and the product has passed the consistency evaluation of the quality and efficacy of generic drugs in early 2021.

Boyer, MD, Clinical Professor of Ophthalmology at the Keck School of Medicine of Southern California and principal investigator of the DIAMOND clinical trial, said: "The way topical drugs are treated will bring important advantages, including early intervention and treatment accessibility, convenience, and non-invasiveness.

Figure 3: Clinical trial of esketamine hydrochloride injection of Yichang Renfu PharmaceuticalSource: Minainet new version of the database Yichang Renfu Pharmaceutical submitted a Class 3 generic marketing application for esketamine hydrochloride injection for the first time in 2020, and was finally approved for clinical trials, and its confirmatory clinical trial was completed in June this year, and the marketing application is now submitted again, which shows that the company attaches great importance to this product.

js?cdnversion='+~(-new Date()/36e5)];Alphyn Biologics, a clinical-stage dermatology company that develops the first multi-target therapeutic, announced January 5 positive results in its Phase 2a clinical trial for the treatment of mild to moderate atopic dermatitis (AD) topical AB-101a.

js?cdnversion='+~(-new Date()/36e5)];Recently, First Drug Holdings (Beijing) Co. js?cdnversion='+~(-new Date()/36e5)];Recently, First Drug Holdings (Beijing) Co. js?cdnversion='+~(-new Date()/36e5)];Recently, First Drug Holdings (Beijing) Co. js?cdnversion='+~(-new Date()/36e5)];Recently, First Drug Holdings (Beijing) Co.

HK) independently developed the world's first innovative drug Aurora (aurora kinase A) inhibitor JAB-2485 phase I/IIa clinical study completed the first dosing of patients with advanced solid tumors in the United States.

VISEN Pharmaceuticals, an innovative biopharmaceutical company focused on endocrine-related therapeutics, announced on January 6 that its Phase 3 clinical trial (PaTHway China trial), an innovative drug in research, has completed a double-blind treatment period on January 4, 2023, and will soon undergo primary endpoint analysis 。 Paroperteitriparatide is administered once daily to restore 24-hour physiological levels of parathyroid hormone (PTH [1-34]) in adult patients with hypoparathyroidism (hypoparathyroidism, HP).

CStone Pharmaceuticals (HKEx: 2616), a leading biopharmaceutical company focused on the development, development and commercialization of innovative immunotherapies and precision therapies for oncolo

js?cdnversion='+~(-new Date()/36e5)];On January 9, the company announced clinical trial data on the combination of its masked anti-CTLA-4 safe antibody SAFEbody ADG126 and anti-PD-1 therapy in patients with advanced/metastatic solid tumors.

js?cdnversion='+~(-new Date()/36e5)];Pufang, a clinical-stage biopharmaceutical company focused on the development of next-generation macromolecule-targeted anti-cancer drugs, announced that its ADC drug PRO1184 (clinical trial number NCT05579366) has completed the first subject administration of the Phase I clinical trial, and the clinical trial application for the ADC drug PRO1160 has been approved by the US Food and Drug Administration (FDA).

According to the announcement, at this stage, Sinovac Pharmaceutical is conducting a "randomized, double-blind, placebo-controlled phase II clinical study of SHEN26 capsules for the treatment of mild and common novel coronavirus infected patients", and the main endpoint indicator is the change in SARS-CoV-2 viral RNA level (RT-PCR test) relative to the baseline.

As a representative enterprise of TCM innovation and transformation that has created an integrated TCM academic innovation and transformation model of "theory + clinical + new drug + experiment + evidence-based", and combines traditional theoretical innovation of TCM with modern science and technology, it is expected to stand out in the wave of TCM innovation and provide a solid fortress for the sustainable and healthy development of the company。 On January 9, Yiling Pharmaceutical closed at 29.

There is a famous "double ten" law in the field of medicine, that is, it takes ten years and one billion dollars to invest a "new drug". The difficulty of new drug research and development is full of

js?cdnversion='+~(-new Date()/36e5)];Bio4t2 inoculated the first patient with T cells containing chimeric antigen receptors (CARs), targeting BT-001 antigen overexpression present in multiple types of solid tumors. js?cdnversion='+~(-new Date()/36e5)];Bio4t2 inoculated the first patient with T cells containing chimeric antigen receptors (CARs), targeting BT-001 antigen overexpression present in multiple types of solid tumors.

1 New Traditional Chinese Medicine Linggui Shugan Granules Launched On December 28, the State Medical Products Administration approved the listing of Kangyuan Pharmaceutical's Class 3. 1 New Traditional Chinese Medicine Linggui Shugan Granules Launched On December 28, the State Medical Products Administration approved the listing of Kangyuan Pharmaceutical's Class 3.